SERAXIS Inc. announces novel method and cell line that generate highly pure populations of insulin-producing cells capable of reversing diabetes in rodents.
GERMANTOWN, Md., Sept. 5, 2018 /PRNewswire/ — SERAXIS Inc., a privately held regenerative medicine company today announced the successful production of stem cell derived pancreatic cells capable of regulating blood glucose in rodent models of insulin dependent diabetes.
URL link to full story
http://seraxis.com/wp-content/uploads/2017/03/Seraxis-Press-Release_Sept-5-2018.pdf
Media Contact
Carole A. Welsch, Ph.D., M.B.A., Chief Business Officer, SERAXIS INC.
301-240-1347